Results 11 to 20 of about 21,294 (218)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors [PDF]

JCO Precision Oncology, 2021
PURPOSE Anaplastic lymphoma kinase ( ALK) rearrangement is a well-known driver oncogene in non–small-cell lung cancer and has also been identified in other types of tumors. However, there is limited evidence on the clinical response to ALK tyrosine kinase inhibitors (TKIs), such as alectinib and crizotinib, in rare tumors with ALK fusion.
Yuki Takeyasu, Hitomi S. Okuma, Yuki Kojima, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Emi Noguchi, Ayumu Arakawa, Taisuke Mori, Kuniko Sunami, Takashi Kubo, Takashi Kohno, Yoshida Akihiko, Noboru Yamamoto, Kan Yonemori   +15 more
openaire   +2 more sources

Tudásmenedzsment és a felsőoktatási intézmény, mint vállalat = Knowledge Management and the University as a Company [PDF]

, 2011
Purpose: ALK rearrangement detection using FISH is the standard test to identify patients with non–small cell lung carcinoma (NSCLC) eligible for treatment with ALK inhibitors. Recently, ALK protein expression in resectable NSCLC showed predictive value.
De Langen, A. J., Dingemans, A. M.C., Groen, H. J.M., Hendriks, L., Hiltermann, T. J.N., Looijen-Salamon, M., Mastik, M. F., Pelgrim, R., Riemersma, S., Schuuring, E., Speel, E. J.M., Staal-Van Den Brekel, J., T Hart, N., Timens, W., Van Den Berg, A., Van Den Borne, B. E., Van Der Heijden, E. H.F.M., Van Der Wekken, A. J., Werner, N.   +18 more
core   +13 more sources

Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan

Journal of International Medical Research, 2022
Objective Anaplastic lymphoma kinase ( ALK ) rearrangement is an important oncogenic driver in some non-small cell lung cancers (NSCLC). Treatment with ALK tyrosine kinase inhibitors improves survival. The availability of diagnostic immunohistochemistry (
Bayan Maraqa, Maxim Al-Ashhab, Maher A. Sughayer   +2 more
doaj   +1 more source

Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)

Frontiers in Oncology, 2020
Background: In patients with anaplastic lymphoma kinase (ALK) rearrangement-positive advanced non–small-cell lung cancer (NSCLC), ALK inhibitors are now the standard treatment, but their clinical efficacy varies widely for each patient.
Meichen Li, Xue Hou, Chengzhi Zhou, Weineng Feng, Guanming Jiang, Hao Long, Shuang Yang, Jing Chen, Na Wang, Kaicheng Wang, Likun Chen   +10 more
doaj   +1 more source

Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment

Frontiers in Oncology, 2022
The anaplastic lymphoma kinase (ALK) gene rearrangement is a driving mutation that underlies about 5-6% of non-small cell lung cancer (NSCLC) cases. Lung cancers that are ALK gene rearrangement-positive can be effectively treated with ALK inhibitors ...
Peng Gao, Kangning Tang, Yuqiu Hao, Wei Li, Xuejiao Lv, Dapeng Li, Yuxi Jia   +6 more
doaj   +1 more source

Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. [PDF]

PLoS ONE, 2013
Patients with ALK gene rearrangements often manifest dramatic responses to crizotinib, an ALK inhibitor. Accurate identification of patients with ALK-positive non-small cell lung cancer (NSCLC) is essential for the clinical application of ALK-targeted ...
Yun-Gang Zhang, Mu-Lan Jin, Li Li, Hong-Ying Zhao, Xuan Zeng, Lei Jiang, Ping Wei, Xiao-Li Diao, Xue Li, Qing Cao, Xin-Xia Tian   +10 more
doaj   +1 more source

Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study

BMC Cancer, 2020
Background Anaplastic lymphoma kinase (ALK) rearrangement is a predictive factor of response to ALK inhibitors in non small cell lung cancer (NSCLC). The prevalence of ALK rearrangements is well known in Whites and Asians.
Hind El yacoubi, Mohamed Lemine Sow, Fouad Kettani, Lamia Gamra, Amina Mestari, Lamia Jabri, Ibrahim Elghissassi, Hassan Errihani   +7 more
doaj   +1 more source

Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer

Molecular Oncology, 2023
ALK rearrangement is called the ‘diamond mutation’ in non‐small cell lung cancer (NSCLC). Accurately identifying patients who are candidates for ALK inhibitors is a key step in making clinical treatment decisions.
Zizong Wang, Yushuai Han, Houquan Tao, Mengxiang Xu, Zhengchuang Liu, Jianhua Zhu, Wei Li, Jie Ma, Zhifang Liu, Weiran Wang, Tonghui Ma   +10 more
doaj   +1 more source

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer [PDF]

Nature Communications, 2021
AbstractALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients, and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple ALK-TKI resistance mutations have been identified from the patients, and several compound mutations, such as I1171N + F1174I or I1171N + L1198H are resistant to all the ...
Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama   +23 more
openaire   +3 more sources

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma

Frontiers in Immunology, 2021
Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-
Wen Dong, Pengfei Lei, Xin Liu, Qin Li, Xiangyang Cheng   +4 more
doaj   +1 more source